50 years of history
With 50 years of experience in the pharmaceutical and medical device fields, Hanmi Science,
Has developed the Ofmom formula, thanks to the close collaboration with scientific organizations worldwide
From the collaboration of our R&D with pediatricians and gastroenterologists,
The Ofmom formula was developed, paying attention to safe regulations established by reference markets (Europe, USA and Asia)
LAUNCHED ‘OFMOM SYNTERACT™ BIMBI’ 14 STICK IN ITALIAN MARKET (DEVELOPED AND MANUFACTURED IN ITALY)
Sponsored SIGENP (Società Italiana di Nutrizione e Gastroenterologia Pediatrica) www.congresso.sigenp.org/2019/home
Sponsored Rome congress 2019 ’10th Probiotics, Prebiotics & New Foods’ (www.probiotics-prebiotics-newfood.com)
Hanmi, co-promoted an agreement of ‘Diquas’ with Santen Pharmaceutical Co., Ltd.
Announced 2018 earnings 880 million of euro in sales, 19% R&D investment against sales
LAUNCHED 'OFMOM PROBIOTICS FORMULA MADE' IN CHINESE MARKET
Set up a maternal and infant biobank in Rome, cooperating with Catholic University of the Sacred Heart and Agostino Gemelli University Policlinic
Established Centre Ofmom and held on the first international symposium on the care of mother and child in Rome
Launched Monterizine Chewable Tab for children
Received FDA orphan drug designation for HM43239 in treatment of AML
Janssen, started phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi
Received industry first ‘BPW Gold Award’ for promoting gender equality
Announced reports 690 million of euro in revenue in 2017.
LAUNCHED ‘ITALIAN PREMIUM LIQUID MILK’ IN ASIAN MARKET (KOREA & CHINA), COLLABORATING WITH GRANAROLO S.P.A.
Co-researched & developed on the public health between Korea and Italy with Catholic University of the Sacred Heart and Agostino Gemelli University General Hospital
Released hypertension-hyperlipidemia three-compound complex Amosartan Q (amlodipine +losartan+rosuvastatin)
Released 3-compound hypertension drug ‘Amosartan Plus (losartan/amlodipine/chlortalidon)’
Launched the first osteoporosis therapy in the world which combines SERM with Vitamin D
Launched ‘Monterizine’, a combination drug for patients with both asthma and allergic rhinitis
Launched ‘Besigum’, a treatment for overactive bladder syndrome treatment
Hanmi-MSD, signed an agreement to export ‘Rosuzet’ to 23 countries
Unveiled new R&D strategy at JP Morgan Healthcare Conference
ESTABLISHED COREE S.R.L. & OFMOM S.R.L. AND CENTRE OFMOM USA
‘Mami Ai’, awarded as the ‘2016 annual trusted intestinal health brand of Chinese mothers’
Presented at the Europe symposium of cancer, the results of the preclinical studies of ‘HM95573 (pan-RAF inhibitor)’
Signed an exclusive license agreement with Genentech for a new oral RAF inhibitor
ESTABLISHED A POSTNATAL CARE CENTER 'CENTRE OFMOM' WHERE PROVIDES PREMIUM SERVICES TO RECOVER MOTHER'S HEALTH AFTER THE CHILDBIRTH
3rd-generation EGFR TKI, HM61713(Olmutinib), received FDA Breakthrough Therapy Designation in lung cancer
Launched oral wound rinse ‘MuGard’ for cancer patients
Hanmi and Sanofi, announced License Agreement to develop Portfolio of Long-Acting Diabetes Treatments
Launched new dual-action hyperlipidemia drug ‘Rosuzet’
Licensed out ‘Poziotinib’ (targeted anticancer agent) to Spectrum Pharma in US
Licensed out immunological therapy ‘HM71224’ to Eli lilly (Deal size : 593 million of euro)
17 million of euro invested in strategic with Allegro Ophthalmics (ophthalmic Bioventure)
Established the first company 'Ofmom' in Hongkong
‘Mami Ai’, Probiotics for kids in Beijing Hanmi, is registered as China Famous Trade Mark
Received ‘fair trade corporation’ award by Fair Trade Commission
Launched ‘Fluterol’, DPI type asthma treatment drug
Launched HIMD for the treatment of gastroesophageal reflux disease, ‘Esomezol’ in the United States
Launched ‘Robelito’, the first ARB-Statin combination drug in Korea, collaborating with Sanofi
Launched ‘Naxozol’, an NSAIDs-PPI combination drug
Exported Hanmi IMD (Esomezol, Amosartan, Pidogul) to seven countries of South-Est Asia through DKSH
Hanmi antibiotic powder injection, achieved the first EU GMP acquisition in the nation
Licensed ‘Amosartan’ in the three states of CIS and Uzbek
Launched ‘Fenocid’ for the management of cholesterol and triglycerides (fatty acids) in the blood.
Selected as a Pharmaceutical Company of Innovation, by Ministry of Welfare
Launched ‘Koennasal spray’ (Hyalu acid+Dexpantenol)
Collaborated on new drug development with Kainos
Received the CE mark for Hyalrheuma from UK SGS
LAPS-GCSF, Collaborated with Spectrum (US)
The 11th Hanmi literature awards
Beijing Hanmi, accredited as ‘R&D Center’ by Beijing Government
Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA
Published Amosartan clinical study on BMC Research Note
Ranked 1st in R&D investment among Korean pharmaceutical companies
Initiated the clinical trials of Amosartan in Europe
Co-promoted an agreement with Lundbeck for Ebixa, a treatment for Alzheimer’s disease
Launched ‘Amosartan’, an antihypertensive combination drug of Amlodipine and Losartan
'Mami Ai', selected Top brand as a medicine for intestinal disorders for children in China
Developed successfully Mexibufen Syrup, using alternative salt
Published clinical study of Amlodipine
Patent for Amlodipine, a new chemical form of Amlodipine salt
Developed Successfully Fedipine table, a 24H controlled-release formulation of Nifedipine
Established Hanmi medicare Co.,Ltd.
Succeeded in the development of the world’s first oral anti-tumor “Paclitaxel”
Made inroads into the European markets through acquisition of Certificates Of Suitability (COS) for the first time in Korea
BROKE 70 MILLION OF EURO BARRIER IN SALES
Established Hanmi Pharmaceutical Co.,Ltd. In China
Launched 'Mami Ai' probiotics for kids
Co-developed an original probiotics medicine studied clinically with Dr. Brochu
Establishment of Hanmi Fine Chemical Co., an affiliated company of Hanmi Pharmaceutical
